Navegar

Colección

Datos Estadísticas

Artículo

Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

One in ten adults has clinically significant subjective tinnitus, and for one in hundred, tinnitus severely affects their quality of life. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. Even a drug that produces a small but significant effect would have a huge therapeutic impact. In the last few years, there have been significant advances in i) the understanding of the pathophysiology of the different forms of tinnitus, ii) the establishment of valid animal models and iii) the development of clinical trial methodology. A glimpse of hope is appearing in the horizon as an increasing number of pharmaceutical industries now have compounds targeting tinnitus in their pipeline. © 2011 Informa UK, Ltd.

Registro:

Documento: Artículo
Título:Emerging pharmacotherapy of tinnitus
Autor:Langguth, B.; Elgoyhen, A.B.
Filiación:University of Regensburg, Interdisciplinary Tinnitus Clinic, Department of Psychiatry and Psychotherapy, Universitaetsstraße 84, 93053 Regensburg, Germany
Instituto de Investigaciones en Ingeniera Genética y Biologa Molecular, Consejo Nacional de Investigaciones Cientficas y Técnicas, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
Departamento de Farmacologa, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina
Palabras clave:Animal models; Anticonvulsants; Antidepressants; Anxiolytics; Auditory system; GABA; Glutamate; Hearing; Inner ear; NMDA; Pain; Phantom perception; Randomized clinical trials; 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine; 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl; 4 aminobutyric acid receptor stimulating agent; am 101; AMPA receptor antagonist; anticonvulsive agent; antidepressant agent; antidiuretic agent; antihistaminic agent; anxiolytic agent; bcg 492a; calcium channel blocking agent; cholinergic receptor blocking agent; cilostazol; clonazepam; dexamethasone; flindokalner; flupentixol; gabapentin; melitracen; n methyl dextro aspartic acid receptor blocking agent; neramexane; neuroleptic agent; oto 104; paroxetine; placebo; sodium channel blocking agent; taurine; unclassified drug; unindexed drug; vestipitant; vigabatrin; acute disease; adjuvant therapy; anxiety disorder; auditory nervous system; chronic disease; clinical trial (topic); controlled clinical trial (topic); depression; drug approval; drug industry; drug targeting; epilepsy; food and drug administration; GABAergic transmission; human; migraine; nerve cell plasticity; neurochemistry; neuropathic pain; nonhuman; pathophysiology; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); quality of life; randomized controlled trial (topic); review; sleep disorder; tinnitus; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Tinnitus; Treatment Outcome
Año:2011
Volumen:16
Número:4
Página de inicio:603
Página de fin:606
DOI: http://dx.doi.org/10.1517/14728214.2011.644273
Título revista:Expert Opinion on Emerging Drugs
Título revista abreviado:Expert Opin. Emerg. Drugs
ISSN:14728214
CODEN:EOEDA
CAS:2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine, 134959-51-6; 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl, 83003-12-7; cilostazol, 73963-72-1; clonazepam, 1622-61-3; dexamethasone, 50-02-2; flindokalner, 183720-28-7, 187523-35-9; flupentixol, 2413-38-9, 2709-56-0; gabapentin, 60142-96-3; melitracen, 5118-29-6; neramexane, 209185-99-9, 219810-59-0, 457068-92-7; paroxetine, 61869-08-7; taurine, 107-35-7; vestipitant, 334476-64-1; vigabatrin, 60643-86-9; Drugs, Investigational
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v16_n4_p603_Langguth

Referencias:

  • Shargorodsky, J., Curhan, G.C., Farwell, W.R., Prevalence and characteristics of tinnitus among US adults (2010) Am J Med, 123 (8), pp. 711-718
  • Langguth, B., A review of tinnitus symptoms beyond 'ringing in the ears': A call to action (2011) Curr Med Res Opin, 27 (8), pp. 1635-1643
  • Langguth, B., Salvi, R., Elgoyhen, A.B., Emerging pharmacotherapy of tinnitus (2009) Expert Opin Emerg Drugs, 14 (4), pp. 687-702
  • Roberts, L.E., Eggermont, J.J., Caspary, D.M., Ringing ears: The neuroscience of tinnitus (2010) J Neurosci, 30 (45), pp. 14972-14979
  • Yang, S., Weiner, B.D., Zhang, L.S., Homeostatic plasticity drives tinnitus perception in an animal model (2011) Proc Natl Acad Sci USA, 108 (36), pp. 14974-14979
  • Rauschecker, J.P., Leaver, A.M., Muhlau, M., Tuning out the noise: Limbic-auditory interactions in tinnitus (2010) Neuron, 66 (6), pp. 819-826
  • De Ridder, D., Elgoyhen, A.B., Romo, R., Langguth, B., Phantom percepts: Tinnitus and pain as persisting aversive memory networks (2011) Proc Natl Acad Sci USA, 108 (20), pp. 8075-8080
  • Wang, H., Brozoski, T.J., Caspary, D.M., Inhibitory neurotransmission in animal models of tinnitus: Maladaptive plasticity (2011) Hear Res, 279 (1-2), pp. 111-117
  • Landgrebe, M., Zeman, F., Koller, M., The tinnitus research initiative (TRI) database: A new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome (2010) BMC Med Inform Decis Mak, 10, p. 42
  • Middleton, J.W., Kiritani, T., Pedersen, C., Mice with behavioral evidence of tinnitus exhibit dorsal cochlear nucleus hyperactivity because of decreased gabaergic inhibition (2011) Proc Natl Acad Sci USA, 108 (18), pp. 7601-7606
  • Brozoski, T.J., Caspary, D.M., Bauer, C.A., Richardson, B.D., The effect of SUPPL.emental dietary taurine on tinnitus and auditory discrimination in an animal model (2010) Hear Res, 270 (1-2), pp. 71-80
  • Zhao, Y., Tzounopoulos, T., Physiological activation of cholinergic inputs controls associative synaptic plasticity via modulation of endocannabinoid signaling (2011) J Neurosci, 31 (9), pp. 3158-3168
  • Zheng, Y., Stiles, L., Hamilton, E., The effects of the synthetic cannabinoid receptor agonists, win55,212-2 and cp55,940, on salicylate-induced tinnitus in rats (2010) Hear Res, 268 (1-2), pp. 145-150
  • Lobarinas, E., By-Brown, W., Stolzberg, D., Effects of the potassium ion channel modulators bms-204352 maxipost and its r-enantiomer on salicylate-induced tinnitus in rats (2011) Physiol Behav, 104 (5), pp. 873-879
  • Piu, F., Wang, X., Fernandez, R., Oto-104: A sustained-release dexamethasone hydrogel for the treatment of otic disorders (2011) Otol Neurotol, 32 (1), pp. 171-179
  • Roberts, C., Inamdar, A., Koch, A., A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus (2011) Otol Neurotol, 32 (5), pp. 721-727
  • Suckfuell, M., Althaus, M., Ellers-Lenz, B., A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus (2011) BMC Ear Nose Throat Disord, 11 (1), p. 1
  • (2011) Neramexane Clin Trial, , http://clinicaltrials.gov/ct2/show/NCT00739635, Available from http://clinicaltrials.gov/ct2/show/NCT00772980, http://clinicaltrials. gov/ct2/show/NCT00827008
  • (2011) BGG492A Clin Trial, , http://clinicaltrials.gov/ct2/show/NCT01302873, Available from
  • (2011) Cilostazol Clin Trial, , http://clinicaltrials.gov/ct2/show/NCT01378650, Available from
  • Meeus, O., De, R.D., Van De, H.P., Administration of the combination clonazepam-Deanxit as treatment for tinnitus (2011) Otol Neurotol, 32 (4), pp. 701-709
  • Muehlmeier, G., Biesinger, E., Maier, H., Safety of intratympanic injection of am-101 in patients with acute inner ear tinnitus (2011) Audiol Neurootol, 16 (6), pp. 388-397
  • (2011) NST001 Clin Trial, , http://clinicaltrials.gov/ct2/show/NCT00957788, Available from

Citas:

---------- APA ----------
Langguth, B. & Elgoyhen, A.B. (2011) . Emerging pharmacotherapy of tinnitus. Expert Opinion on Emerging Drugs, 16(4), 603-606.
http://dx.doi.org/10.1517/14728214.2011.644273
---------- CHICAGO ----------
Langguth, B., Elgoyhen, A.B. "Emerging pharmacotherapy of tinnitus" . Expert Opinion on Emerging Drugs 16, no. 4 (2011) : 603-606.
http://dx.doi.org/10.1517/14728214.2011.644273
---------- MLA ----------
Langguth, B., Elgoyhen, A.B. "Emerging pharmacotherapy of tinnitus" . Expert Opinion on Emerging Drugs, vol. 16, no. 4, 2011, pp. 603-606.
http://dx.doi.org/10.1517/14728214.2011.644273
---------- VANCOUVER ----------
Langguth, B., Elgoyhen, A.B. Emerging pharmacotherapy of tinnitus. Expert Opin. Emerg. Drugs. 2011;16(4):603-606.
http://dx.doi.org/10.1517/14728214.2011.644273